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Abstract
The combination of arterial hypertension, asthma and COPD has a significant prevalence in clinical practice. The presence of
hypertension contributes to the growth of severity of asthma-COPD overlap (ACO), the worst prognosis and a high risk of
cardiovascular complications. Coexistence of diseases changes the course of each of them, contributes to the early formation
of complications and creates certain difficulties for therapy.
The aim of work was to investigate the factors of cardiovascular risk, as well as the arterial pressure indicators of patients
with ACO.
Patients. 140 patients with ACO with an average forced expiratory volume for the first second (FEV1) (59.0±1.4)% and
the ratio of forced expiratory volume in the first second to the forced vital capacity of the lungs (FEV1 / FVC) (53.6±0.8)%.
Methods. All the patients underwent measurement of body weight and height, measurement of office systolic blood pressure
(SBP), diastolic blood pressure (DBP), 24-hour ambulatory blood pressure monitoring (ABPM), biochemical blood test,
coagulogram, assessment of total cardiovascular risk on a SCORE scale, the risk of cardiovascular complications on QRISK2
scale, the risk of developing diabetes mellitus (DM) on QDiabetes scale.
Results. Patients with ACO had some pathological changes in blood pressure. Also, these patients had a significant
overload with arterial pressure. Also, in these patients, the diurnal index (DI) of SBP and DI DBP were significantly reduced
relatively to normal values.
Patients with ACO predominantly belonged to the group of moderate risk of fatal cardiovascular events in 10 years (3.83%).
The QRISK2 is quite significant, and is more than 15%. There is also a fairly significant risk of developing DM (more than
13%).
A higher concentration of inflammational markers was revealed in ACO patients with more severe bronchial obstruction
(significant increase in C-reactive protein and fibrinogen with increased bronchial obstruction).
ACO patients from subgroups GOLD 1 and GOLD 2 predominantly belonged to the group of moderate risk, and patients
from the GOLD 3. 4 subgroup predominantly had a high risk of developing fatal cardiovascular events over the next 10 years
(according to the SCORE scale). The QRISK2 scale risk was also moderate in the first two subgroups and high in patients
with severe bronchial obstruction (GOLD 3, 4).
Conclusions. In patients with a combination of asthma and COPD, significant cardiovascular comorbid pathology, a high
prevalence of arterial hypertension, a high degree of overload with arterial pressure were found. Significant violations of the
variability of blood pressure were also revealed. In this category of patients, a moderate risk of developing fatal cardiovascular
events, as well as the development of diabetes within the next 10 years is also determined. Even more significant violations
of blood pressure and high rates of cardiovascular risk were detected in patients with a combined pathology with a higher
degree of bronchial obstruction.
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Problem statement and analysis of the
recent research
The number of patients with obstructive lung disease in Ukraine
and worldwide is constantly growing, and the number of pa-
tients with bronchial obstruction and co-existent cardiovas-
cular pathology increases as well. Common risk factors for
bronchial obstruction and cardiovascular diseases, namely
tobacco smoking, unhealthy habits, low physical activity, mal-
nutrition, etc., create the preconditions for a combined clinical
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course of these pathological conditions. Concomitant diseases
significantly affect the patient’s condition aggravating the clin-
ical course of the underlying disease; their presence may affect
the prognosis and the survival of patients [1, 2, 3, 4, 5, 6]. The
co-existence of arterial hypertension (AH), bronchial asthma
(BA) and chronic obstructive pulmonary disease (COPD) has
a significant prevalence. The presence of AH contributes to
the increase in severity of BA and COPD, worse prognosis
and a high risk of cardiovascular complications [7, 8]. The
co-existence of diseases changes their clinical course as well
as contributes to early formation of complications and creates
certain difficulties for therapy. In modern consensuses on the
management of bronchial obstruction, a special emphasis has
been put on treatment of comorbid pathologies and conditions
[9, 10].
AH is known to be one of the main risk factors for the de-
velopment of cardiovascular complications thereby deserving
priority attention. Many studies have proven the priority of
AH in the development of stroke and myocardial infarction,
which determine the increase in disability and premature mor-
tality [11, 12, 13, 14]. At the same time, there is a certain
underdiagnosis, untimely detection of high blood pressure
(BP) in patients with BA and COPD.
The objective of the research was to investigate the fac-
tors for cardiovascular risk as well as BP parameters in pa-
tients with BA and COPD.
1. Materials and methods
The study was agreed with the ethics committee of the Na-
tional Institute of Phthisiology and Pulmonology named after
F.G. Yanovsky of National Academy of Medical Sciences of
Ukraine; all the participants were acquainted with the protocol
of research and signed informed consent to participate in the
study. The work was carried out at the expense of the state
budget of Ukraine.
The study included 140 patients with bronchial asthma and
chronic obstructive pulmonary disease - the average forced ex-
piratory volume in the first one second (FEV1) (59.0±1.4) %
and the ratio of forced expiratory volume in the first second to
the forced vital capacity of the lungs (FEV1/FVC) (53.6±0.8)
%. In 91 patients, the disease made its debut as BA - a sub-
group of “primary BA and concomitant pathology”. Their
FEV1 was (60.7±1.7) %, FEV1/FVC was (54.2±1.0) %. In
49 other cases, the initial diagnosis was COPD - a subgroup
of “primary COPD and concomitant pathology” and their
FEV1 was (56.0±2.5) % and FEV1/FVC ratio was (52.5±1.4)
%. Characteristics of patients are given in Table 1. All the
patients underwent the following examinations: height and
weight measurements, office systolic blood pressure (SBP)
and diastolic blood pressure (DBP) measurements, 24-hour
ambulatory blood pressure monitoring (24-hour ABPM), bio-
chemical blood analysis, coagulogram.
Biochemical analyzes were performed using the biochem-
ical analyzer Vitalab Selectra E (Netherlands) in the clinical
and biochemical laboratory of the National Institute of Ph-
thisiology and Pulmonology named after F.G. Yanovsky of
National Academy of Medical Sciences of Ukraine. The lev-
els of creatinine, glucose, total cholesterol (TC), triglycerides
(TG), uric acid, and total serum protein were determined.
The prothrombin index (PTI), blood recalcification time, fib-
rinogen and fibrin levels were determined manually using a
thermostat with transparent walls. Creatinine clearance re-
flecting the glomerular filtration rate (GFR), was estimated
using the Cockroft-Gault formula [15]. The level of highly
specific C-reactive protein was determined in the Clinical
Immunology Laboratory of the National Institute of Phthisiol-
ogy and Pulmonology named after F.G. Yanovsky of National
Academy of Medical Sciences of Ukraine.
ABPM was done by means of the portable device EC-
3H/ABP (Labtech, Hungary). The following indicators were
studied: daily average (24-hour), daytime, night-time SBP,
DBP, pulse blood pressure (PBP), heart rate (HR). In com-
puter analysis of 24-hour ABPM for SBP and DBP, there was
calculated the time index (TI) which characterizes BP over-
load during the day and is defined as the percentage of BP
measurements exceeding 140/90 mm Hg during the day and
120/80 mm Hg at night. The area under the curve (AUC) of
AH was determined, which is the area between the curve of
elevated BP and the line of the limit of normal; the variability
was calculated as the standard deviation of BP value. In addi-
tion, using software, the diurnal index (DI) was calculated -
the percentage of decrease in night-time BP blood pressure as
compared to daytime BP.
The DI reflects the variability of BP as well as represents
the difference between the average values of daytime BP and
night-time BP as a percentage. Normal DI is 10-25%, i.e., the
average level of night-time BP should be no less than 10%
lower than the average daytime BP [16, 17].
The data of modern studies indicate the significance of
determining the variability of the diurnal rhythm of BP as
an additional predictor of clinical cardiovascular events [18,
19, 20]. The European Society of Cardiology Guidelines
for the Management of Arterial Hypertension emphasize the
importance of the 24-hour ABPM as well, as numerous studies
have shown that daily BP better correlates with morbidity
and mortality than office BP [12, 19]. Circadian rhythm
disturbances with an insufficient reduction in night-time BP
were found to be associated with a higher incidence of stroke,
albuminuria, more frequent development of left ventricular
hypertrophy, coronary heart disease (CHD), cardiovascular
events and fatal events [20, 21, 22, 23, 24].
According to the data of 24-hour ABPM, PBP<45 mm
Hg, as proposed by P. Verdecchia, was used as the normal
range for PBP [25].
The value of hypertension TI<25% referred to the nor-
mal values; the value of hypertension TI >25% referred to
pathological values being typical for AH [17, 18].
There were used standard values of BP recommended
by the European Society of Cardiologists and the Ukrainian
Association of Cardiologists [11, 12].
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Table 1. Characteristics of patients
Parameters Patients with BA and COPD (n =140)
Sex, (n) 74 women, 66 men
Age, years 5.56±0.81
Body mass index, kg/m2 28.82±0.43
Smoking history, pack years 10.35±1.77
Ex-smokers, (%) 7
Smokers, (%) 34
Never-smokers, (%) 59
Asthma severity
Mild persistent, (%) 6
Moderate persistent, (%) 79
Severe persistent, (%) 15
Global Initiative for Obstructive Lung Disease (GOLD) groups
A (%) 13
B (%) 21
C (%) 20
D (%) 46
GOLD COPD stages
1, (%) 29
2, (%) 58
3, (%) 11
4, (%) 2
Past AH, % 65
Taking of β -blockers, % 7
Taking of angiotensin-converting-enzyme inhibitors,
%
29
Taking of diuretics, % 21
Taking of calcium antagonists, % 16
Taking of angiotensin II receptor blockers, % 14
BP was measured at regular intervals - every 15 minutes
in the daytime and every 30 minutes at night (from 10 pm
to 6 am). Patients followed a normal lifestyle, doing nor-
mal physical activities at home. The accumulation of data
and their mathematical processing were carried out using li-
censing software products included in the package Microsoft
Office Professional 2007, license Russian Academic OPEN
No Level # 43437596. Statistical processing was performed
using mathematical and statistical functions of MS Excel, as
well as additional statistical functions developed by S.N. La-
pach, A.V. Chubenko, P.N. Babich. The studied parameters
were evaluated using the mean value (M), the error of the
mean value (m), test of statistical significance (t), significance
value (p), followed by the comparison using the Student’s
t-test and the Mann-Whitney U test depending on the type
of data distribution.The verification of the numeric rows for
compliance with the normal distribution was carried out using
the special function NORMSAMP 1 developed for the Excel
program.
2. Results
According to 24-hour ABPM, in patients with BA and COPD,
there were some pathological changes in BP. The average
24-hour DBP, 24-hour PBP, night-time SBP and night-time
DBP increased. BP overload was observed as well (elevated
mean 24-hour SBP TI and 24-hour DBP TI, average daytime
SBP TI and DBP TI, and significantly increased night-time
SBP TI and DBP TI). The main BP load in patients with a
concomitant pathology occurred during the passive period
of the day, which may be caused by nocturnal symptoms
of bronchial obstructive diseases. In addition, SBP DI and
DBP DI reduced significantly as compared to normal values
indicating an unsatisfactory decrease in BP at night, which
may be caused by the effect of bronchial and obstructive
pathology. The data are presented in Table 2.
In patients with BA and COPD, biochemical blood param-
eters as well as blood coagulation parameters were within the
limits of norm, except elevated levels of TC and C-reactive
protein. The data are presented in Table 3.
The calculation of total cardiovascular risk is an integral
part of the strategy aimed at preventing new cases of cardio-
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Table 2. BP parameters according to office measurement and 24-hour ABPM in patients with BA and COPD
BP parameters Patients with BA and COPD
Office SBP, mm Hg 135.57±1.6
Office DBP, mm Hg 82.04±0.69
24-hour SBP, mm Hg 129.76±1.33
24-hour DBP, mm Hg 81.34±0.81
24-hour PBP, mm Hg 47.89±0.77
SD of 24-hour SBP, mm Hg 17.18±0.52
SD of 24-hour DBP, mm Hg 12.96±0.42
24-hour SBP TI, % 40.25±2.42
24-hour DBP TI, % 31.31±2.15
24-hour SBP AUC, mm Hg/hour 379.59±18.09
24-hour DBP AUC, mm Hg/hour 277.99±14.16
Daytime SBP, mm Hg 131.86±1.38
Daytime DBP, mm Hg 83.87±0.88
Daytime PBP, mm Hg 47.49±0.78
SD of daytime SBP, mm Hg 16.49±0.6
SD of daytime DBP, mm Hg 12.27±0.5
Daytime SBP TI, % 33.68±2.54
Daytime DBP TI, % 29.36±2.36
Daytime SBP AUC, mm Hg/hour 348.68±20.82
Daytime DBP AUC, mm Hg/hour 310.2±20.82
Night-time SBP, mm Hg 125.14±1.5
Night-time DBP, mm Hg 75.25±0.81
Night-time PBP, mm Hg 49.46±0.95
SD of night-time SBP, mm Hg 13.65±0.51
SD of night-time DBP, mm Hg 10.09±0.42
Night-time SBP TI, % 56.85±2.93
Night-time DBP TI, % 35.53±2.63
Night-time SBP AUC, mm Hg/hour 408.1±22.86
Night-time DBP AUC, mm Hg/hour 226.04±20.1
SPB DI, % 4.78±0.8
DBP DI, % 9.23±0.78
Note.
SD - standard deviation.
vascular disease. One of the main tools for assessing car-
diovascular risk is the Systematic Coronary Risk Evaluation
(SCORE) charts according to which any patient who has a 5%
risk of death due to cardiovascular disease within the next 10
years is considered as a high-risk person. The SCORE charts
include five risk factors: age, gender, SBP, smoking status
and blood cholesterol levels. According to the indicator of
cardiovascular risk obtained using the SCORE charts, all the
patients are divided into four risk groups – low risk, moderate
risk, high risk or very high risk. The group of low cardiovas-
cular risk - a 10-year risk of any fatal cardiovascular event is
<1%; the group of moderate cardiovascular risk - a 10-year
risk of any fatal cardiovascular event is 1-5%; the group of
high cardiovascular risk - a 10-year risk of any fatal cardiovas-
cular event is 5-10%; the group of very high cardiovascular
risk - a 10-year risk of any fatal cardiovascular event is ≥10%
[26]. Patients with BA and COPD were predominantly at a
moderate risk of fatal cardiovascular events within the next 10
years (3.83%). Fig.1 demonstrates the distribution of patients
with BA and COPD according to the degree of cardiovascular
risk.
The risk of cardiovascular complications (stroke and my-
ocardial infarction (MI)) within the next 10 years was cal-
culated using the QRISK2 algorithm [27]. In patients with
a comorbidity, the risk of developing cardiovascular compli-
cations within the next 10 years was quite significant being
more than 15%.
The risk of developing diabetes mellitus (DM) within
the next 10 years was assessed according to the QDiabetes
algorithm [28]. In patients with BA and COPD, there was
found a significant risk of developing diabetes mellitus (more
than 13%). The data are presented in Table 4.
Evaluation of Cardiovascular Risk and Blood Pressure Parameters in Patients with Bronchial Asthma and
Co-Existent Chronic Obstructive Pulmonary Disease — 5/11
Table 3. Biochemical blood parameters, blood coagulation parameters and inflammation parameters in patients with BA and
COPD
Parameters Patients with BA and COPD Normal range
Blood glucose, mmol/l 5.91±0.17 3.6-6.2
Creatinine, µmol/l 91.68±1.41 53-115
GFR, ml/min 83.56±2.14 80-130 (men), 90-150 (women)
Uric acid, µmol/l 265.86±9.7 155-428
TC, mmol/l 7.04±1.15 3-5.1
TG, mmol/l 1.5±0.06 0.5-1.7
Total protein, g/l 73.33±0.71 65-85
C-reactive protein, mg/l 12.31±1.07 0-6
PTI, % 94.1±0.79 80-100
Recalcification time, s 89.87±2.41 60-120
Fibrinogen, mg 360.36±8.91 200-400
Fibrin, mg 17.43±0.39 10-20
Figure 1. SCORE risk charts in patients with BA and COPD
According to the SCORE charts, cardiovascular risk was
significantly higher in patients with primary COPD (4.65±0.57%
vs. 3.38±0.34% in patients with primary BA) (p<0.05). We
have analyzed the differences in BP parameters in patients
with different degrees of bronchial obstruction. To divide
patients according to the severity of bronchial obstruction, the
GOLD criteria were used (Table 5) [9].
Since only 2 patients were in Group 4 group, Group 3 and
Group 4 were combined for data analysis.
When comparing 24-hour ABPM indices, 24-hour SBP
TI and night-time DBP TI were higher in Group 2 as com-
pared to those in Group 1 (45.27±3.15 vs. 31.78±4.44 and
40.01±3.57 vs. 28.02±4.59, p <0.05); daytime DBP AUC
was higher in Group 2 (342.53±29.3 vs. 259.73±29.42,
p<0.05) as well. BP overload was somewhat higher in Group
2.
SBP DI and DBP DI were significantly higher in Group 1
than in Group 3 and Group 4 (6.57±1.39 vs. 0.39±2.22 for
SBP and 10.85±1.35 vs. 3.61±2.28 for DBP) (p<0.05). DBP
DI in Group 3 and Group 4 was significantly lower than that in
Group 2 (9.69±1.0) (p<0.05), i.e., the decrease in the FEV1
was accompanied by adverse dynamics of BP DI. Possible
mechanism of this observation is the negative impact of night-
time manifestations and symptoms of bronchial obstruction
on physiological circadian rhythms of patients, and as a result,
insufficient reduction in BP at night.
A higher concentration of systemic inflammation mark-
ers was found in patients with severer bronchial obstruction
(a significant increase in C-reactive protein and fibrinogen
levels with an increase in bronchial obstruction). According
to previous studies, in patients with COPD, there was found
the presence of inflammation not only in the lungs but also
in the peripheral blood with an increase in the concentration
of systemic inflammatory biomarkers (C-reactive protein, fib-
rinogen, peripheral blood neutrophils, etc.), which further
contributes to hypercoagulation and is an unfavorable pre-
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Table 4. Risk indicators in patients with BA and COPD
Indicators Patients with BA and COPD
Cardiovascular risk according to the SCORE charts, % 3.83±0.3
Risk of developing DM (the QDiabetes algorithm), % 13.99±1.08
Cardiovascular risk according to the QRISK2 algorithm, % 15.77±1.0
Table 5. Classification of bronchial obstruction severity in COPD by the level of the FEV1 after the administration of
bronchodilators (GOLD, 2017)
Stage FEV1, %
GOLD 1 FEV1≥80 %
GOLD 2 50≤ FEV1<80 %
GOLD 3 30≤ FEV1<50 %
GOLD 4 FEV1<30 %
dictor of complications [29, 30]. There are some studies on
the association of BA with the indicators of systemic inflam-
mation (C-reactive protein, fibrinogen) [31, 32]. The results
obtained by us are presented in Table 6.
Patients of Group 1 and Group 2 were predominantly
at a moderate risk of fatal cardiovascular events within the
next 10 years, while patients of Group 3 and Group 4 were
predominantly at a high risk of developing fatal cardiovascular
events within the next 10 years (according to the SCORE
charts).
The risk of developing cardiovascular complications ac-
cording to the QRISK2 algorithm was moderate in the first
two groups and high in patients with severe bronchial obstruc-
tion (Group 3 and Group 4). The data are presented in Table
7.
Among patients with BA and COPD, there was a consid-
erable number of individuals with excess body weight and
obesity. Considering the proven influence of obesity on the
level of BP and the development of AH, patients were divided
into 3 groups according to the body mass index (BMI): pa-
tients with normal body weight (the BMI less than 25 kg/m2),
patients with excess body weight (the BMI - 25-30 kg/m2)
and obese patients (the BMI greater than 30 kg/m2). The
parameters of office BP and 24-hour ABPM are presented in
Table 8.
In patients with obesity, there were higher indicators of
office and 24-hour ABPM: 24-hour SBP and 24-hour DBP,
24-hour PBP, 24-hour SBP TI and 24-hour DBP TI; similar
changes were observed during both the active and passive pe-
riods of the day. High PBP was recognized as an independent
risk factor for CHD in the Framingham Heart Study; it is an
independent risk factor for total, cardiovascular and coronary
mortality as well [25, 33]. The Sleep Apnea Cardiovascular
Endpoints (SAVE) study has found that high PBP is a strong
independent predictor of adverse events after MI in patients
with left ventricular systolic dysfunction [34].
PBP varies both with the patients’ age and under the influ-
ence of processes occurring in cardiovascular diseases – AH,
DM, hypercholesterolemia, and in the end-stages of kidney
disease. These changes occur due to changes in arterial stiff-
ness. They can be detected even before clinical manifestations
of vascular disease. Arterial stiffness may be a marker for
the onset of atherosclerotic disease in the future, and directly
affect the atherosclerotic process as well as the formation of
isolated systolic hypertension [35]. In patients with BA and
COPD, PBP was significantly higher in concomitant obesity.
According to the 24-hour ABPM, in patients with excess
body weight, changes in BP were not pronounced; however,
parameters indicating BP overload (24-hour SBP AUC and
24-hour DBP AUC), night-time SBP, night-time SBP AUC
were higher than those in patients with normal body weight
and the indicator indicating lowered BP variability (DBP DI)
was lower.
Recently, more and more data on the role of uric acid in
the development of cardiovascular disease have been accu-
mulated. Patients with AH, CHD, heart failure and/or kidney
impairment have been found to have higher levels of uric
acid as compared to healthy individuals. Malignant AH is
associated with a significant increase in uric acid as well [36,
37, 38]. In group of patients with BA and COPD, uric acid
was within the normal range, but in concomitant obesity, the
indicator was significantly higher. The data are presented in
Table 9.
The risk of fatal cardiovascular events and cardiovascular
complications increased in patients with a comorbidity in the
presence of excess body weight and obesity; however, the
indicators did not reach statistical significance. In patients
with BA and COPD, with an increase in the BMI, the risk
of developing DM within the next 10 years significantly in-
creased: in concomitant obesity, it was more than 24%. The
data are presented in Table 10.
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Table 6. Biochemical blood parameters, blood coagulation parameters and inflammation parameters in patients with BA and
COPD depending on the degree of bronchial obstruction
Parameters Group 1 (n=41) Group 2 (n=81) Group 3, 4 (n=18)
Blood glucose, mmol/l 5.49±0.27 6.08±0.26 6.08±0.32
Creatinine, µmol/ l 92.57±2.65 90.43±1.81 95.27±4.42
GFR, ml/min 85.68±4.04 84.05±2.91 76.5±4.88
Uric acid, µmol/l 251.64±20.26 268.76±12.51 284.09±23.22
TC, mmol/l 6.3±0.24 7.77±1.98 5.35±0.3
TG, mmol/l 1.5±0.12 1.49±0.08 1.32±0.21
Total protein, g/l 71.83±2.07 73.96±0.63 73.88±1.2
C-reactive protein, mg/l 8.66±1.43 13.37±1.57* 15.95±2.94*
PTI, % 94.27±1.54 95.04±0.94 89.5±2.75
Recalcification time, s 94.8±7.86 87.85±1.13 87.72±3.85
Fibrinogen, mg 347.44±16.7 395.46±11.57* 387.44±24.15
Fibrin, mg 16.2±0.67 18.01±0.52* 17.61±1.1
Note.
* - p<0.05; ** - p<0.01 compared to Group 1
Table 7. Risk indicators in patients with BA and COPD depending on the degree of bronchial obstruction
Indicators Group1 Group 2 Group 3,4
(n=41) (n=81) (n=18)
Cardiovascular risk according to the SCORE charts, % 3.27±0.53 3.69±0.39 5.72±0.84* α
Risk of developing DM (the QDiabetes algorithm), % 12.45±1.69 14.9±1.53 13.61±3.4
Cardiovascular risk according to the QRISK2 algorithm, % 12.48±1.75 15.9±1.24 22.69±3.33** α
Note.
* - p<0.05; ** - p<0.01 compared to Group 1;
α - p<0.05; α α - p<0.01 compared to Group 2
3. Conclusions
In patients with a co-existence of BA and COPD, a signifi-
cant cardiovascular comorbidity was found, namely a high
prevalence of AH and a high degree of BP overload being es-
pecially pronounced at night, possibly due to severe symptoms
of bronchial obstructive pathology.
Significant abnormalities in BP variability and a high car-
diovascular risk caused by increased PBP were observed as
well. In this category of patients, a moderate risk of devel-
oping fatal cardiovascular events as well as cardiovascular
complications (MI and stroke) and DM within the next 10
years was determined.
According to 24-hour ABPM, even more significant ab-
normalities in BP and high rates of cardiovascular risk were
detected in patients with severer degree of bronchial obstruc-
tion and concomitant obesity.
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Table 8. BP parameters according the office measurement and 24-hour ABPM in patients with BA and COPD depending on
body weight
BP parameters BMI <25 (n=32) BMI 25-30 (n=50) BMI>30 (n=58)
Office SBP, mm Hg 132.34±2.4 135.86±1.96 137.1±3.25
Office DBP, mm Hg 78.91±1.2 81.66±1.03 84.1±1.22**
24-hour SBP, mm Hg 124.41±2.55 129.24±2.28 133.16±2.05**
24-hour DBP, mm Hg 79.0±1.7 80.98±1.36 82.95±1.25*
24-hour PBP, mm Hg 44.84±1.3 47.66±1.3 49.76±1.27**
SD of 24-hour SBP, mm Hg 16.88±1.0 17.8±0.84 16.81±0.87
SD of 24-hour DBP, mm Hg 12.06±0.94 13.58±0.65 12.93±0.69
24-hour SBP TI, % 31.97±4.94 39.06±4.18 45.84±3.68*
24-hour DBP TI, % 24.94±4.43 30.38±3.53 35.64±3.43*
24-hour SBP AUC, mm Hg/hour 313.59±33.32 409.06±29.03* 390.59±30.6
24-hour DBP AUC, mm Hg/hour 219.25±26.98 313.0±23.7* 280.21±22.56
Daytime SBP, mm Hg 127.13±2.53 130.56±2.36 135.6±2,21*
Daytime DBP, mm Hg 82.16±1.66 83.04±1.47 85.53±1.44
Daytime PBP, mm Hg 44.59±1.24 47.02±1.31 49.5±1.33**
SD of daytime SBP, mm Hg 15.97±1.07 17.64±1.0 15.79±1.02
SD of daytime DBP, mm Hg 11.06±1.09 13.54±0.8 11.84±0.79
Daytime SBP TI, % 26.03±4.9 32.08±4.23 39.28±4.09*
Daytime DBP TI, % 24.25±4.86 27.8±3.68 33.52±3.93
Daytime SBP AUC, mm Hg/hour 310.09±49.99 378.2±31.61 344.52±32.73
Daytime DBP AUC, mm Hg/hour 277.03±53.46 341.5±32.29 301.52±30.59
Night-time SBP, mm Hg 118.16±2.87 125.88±2.62* 128.36±2.27**
Night-time DBP, mm Hg 72.0±1.6 75.92±1.32 76.47±1.33*
Night-time PBP, mm Hg. 45.78±1.86 49.54±1.79 51.43±1.32*
SD of night-time SBP, mm Hg 13.97±0.97 13.1±0.81 13.95±0.87
SD of night-time DBP, mm Hg 9.9±0.75 9.22±0.69 10.95±0.71
Night-time SBP TI, % 45.13±6.29 53.5±4.9 66.21±4.29** α
Night-time DBP TI, % 25.44±5.07 36.0±4.74 40.67±3.92*
Night-time SBP AUC, mm Hg/hour 311.47±38.55 433.46±41.0* 439.55±36.13*
Night-time DBP AUC, mm Hg/hour 209.28±49.71 225.84±36.34 235.45±26.3
SPB DI, % 6.63±1.55 2.9±1.39 5.37±1.25
DBP DI, % 11.94±1.18 7.31±1.33* 9.37±1.32
Note.
* - p<0.05; ** - p<0.01 compared to patients with the BMI <25;
α - p<0.05; α α - p<0.01 compared to patients with the BMI of 25-30
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Table 9. Biochemical blood parameters, blood coagulation parameters and inflammation parameters in patients with BA and
COPD depending on the degree of body weight
Parameters BMI <25 (n=32) BMI - 25-30 (n=50) BMI>30 (n=58)
Blood glucose, mmol/l 5.65±0.46 5.99±0.3 5.97±0.22
Creatinine, µmol/l 88.02±2.85 93.57±2.67 92.07±1.97
GFR, ml/min 68.75±3.09 77.02±2.3* 97.36±3.77** α α
Uric acid, µmol/l 220.48±18.64 263.77±16.06 292.25±15.24**
TC, mmol/l 10.67±5.07 5.82±0.2 6.06±0.16
TG, mmol/l 1.0±0.07 1.57±0.13** 1.65±0.08**
Total protein, g/l 73.43±1.11 74.55±0.77 72.22±1.47
C-reactive protein, mg/l 10.52±2.4 11.48±1.66 14.01±1.73
PTI, % 92.66±1.66 95.54±1.39 93.66±1.19
Recalcification time, s 90.22±1.49 87.68±2.11 91.57±5.53
Fibrinogen, mg 408.38±17.55 375.88±14.77 368.78±14.48
Fibrin, mg 18.56±0.8 17.14±0.67 17.05±0.6
Note.
* - p<0.05; ** - p<0.01 compared to patients with the BMI <25;
α - p<0.05; α α - p<0.01 compared to patients with the BMI of 25-30
Table 10. Risk indicators in patients with BA and COPD depending on body weight
Indicators BMI<25 (n=32) BMI - 25-30 (n=50) BMI>30 (n=58)
Cardiovascular risk accord-
ing to the SCORE charts, %
3.56±0.6 3.62±0.46 4.16±0.51
Risk of developing DM (the
QDiabetes algorithm), %
4.14±0.48 7.9±0.85** 24.93±1.57** α α
Cardiovascular risk accord-
ing to the QRISK2 algo-
rithm, %
15.07±2.32 14.36±1.77 17.37±1.39
Note.
* - p<0.05; ** - p<0.01 compared to patients with the BMI <25;
α - p<0.05; α α - p<0.01 compared to patients with the BMI of 25-30
